Place · Level 3 · Condition
Osteoporosis
DXA T + FRAX · 髋骨折 1 年死亡 20-30% · 钙+D+蛋白+力量 · 双膦/Denos/Romo · 围绝经窗口
Story path
Chapter 1
The silent killer
The silent killer
Osteoporosis = progressive decline in bone mineral density and microarchitecture → ↑ risk of fragility fracture.
Epidemiology (China 2018 survey):
32% of 65+ y/o women + 6% of men have osteoporosis~ 19% of 50+ y/o women + 6% of men~ 2 million fragility fractures per yearHip-fracture 1-year mortality 20-30%, residual disability 40-50%One of the leading causes of disability in older adults
WHO osteoporosis definition (DXA T-score):
Normal: T ≥ -1.0Osteopenia: -2.5 < T < -1.0Osteoporosis: T ≤ -2.5Severe osteoporosis: T ≤ -2.5 + any fragility fracture
DXA:
Lumbar spine + hip + femoral neck standard sitesScreening: women 65+, men 70+ (any) / 60+ (with risk)
Risk factors:
Non-modifiable: female + older age + family history + early menopause + Caucasian / Asian + small frameModifiable:Insufficient calcium / D / protein intakeSedentary lifestyleSmoking + heavy alcoholLow body weight (BMI < 18.5)Long-term steroids (≥ 5 mg prednisone-equivalent ≥ 3 months)Hypogonadism (low T / low E2)Hyperthyroidism / hyperparathyroidism / Cushing'sEstrogen blockers (aromatase inhibitors for breast cancer)Long-term PPI / anticonvulsants / SSRI / chemotherapy
FRAX assessment (Kanis 2008):
10-year major + hip-fracture probabilityIntegrates age / sex / BMI / risk factors / DXAOnline tool: FRAX.shef.ac.uk (China model available)DXA + FRAX combined drives treatment
Common osteoporotic fracture sites:
Vertebral compression (most common, 50%+ of patients): sudden back pain; some asymptomatic and only found on X-ray → height loss + kyphosisHip fractures (femoral neck / intertrochanteric): the most serious in older adultsDistal radius (Colles' fracture): from a fall onto an outstretched hand; common first presentation in middle-aged womenProximal humerus / ribs / pelvis: other fragility sites
"The postmenopausal window" (atlas perimenopause L4):
Bone loss is fastest in the first 5-10 years post-menopause (-2-5%/year)Building reserve at 35-50 + early intervention at menopause = the key to lifelong bone health
Epidemiology (China 2018 survey):
32% of 65+ y/o women + 6% of men have osteoporosis~ 19% of 50+ y/o women + 6% of men~ 2 million fragility fractures per yearHip-fracture 1-year mortality 20-30%, residual disability 40-50%One of the leading causes of disability in older adults
WHO osteoporosis definition (DXA T-score):
Normal: T ≥ -1.0Osteopenia: -2.5 < T < -1.0Osteoporosis: T ≤ -2.5Severe osteoporosis: T ≤ -2.5 + any fragility fracture
DXA:
Lumbar spine + hip + femoral neck standard sitesScreening: women 65+, men 70+ (any) / 60+ (with risk)
Risk factors:
Non-modifiable: female + older age + family history + early menopause + Caucasian / Asian + small frameModifiable:Insufficient calcium / D / protein intakeSedentary lifestyleSmoking + heavy alcoholLow body weight (BMI < 18.5)Long-term steroids (≥ 5 mg prednisone-equivalent ≥ 3 months)Hypogonadism (low T / low E2)Hyperthyroidism / hyperparathyroidism / Cushing'sEstrogen blockers (aromatase inhibitors for breast cancer)Long-term PPI / anticonvulsants / SSRI / chemotherapy
FRAX assessment (Kanis 2008):
10-year major + hip-fracture probabilityIntegrates age / sex / BMI / risk factors / DXAOnline tool: FRAX.shef.ac.uk (China model available)DXA + FRAX combined drives treatment
Common osteoporotic fracture sites:
Vertebral compression (most common, 50%+ of patients): sudden back pain; some asymptomatic and only found on X-ray → height loss + kyphosisHip fractures (femoral neck / intertrochanteric): the most serious in older adultsDistal radius (Colles' fracture): from a fall onto an outstretched hand; common first presentation in middle-aged womenProximal humerus / ribs / pelvis: other fragility sites
"The postmenopausal window" (atlas perimenopause L4):
Bone loss is fastest in the first 5-10 years post-menopause (-2-5%/year)Building reserve at 35-50 + early intervention at menopause = the key to lifelong bone health
FRAX practical + treatment tree
FRAX is not a single number — it is a decision tool. Yet many clinicians and patients don't know how to use it. Here is the practical breakdown.FRAX inputs (online tool frax.shef.ac.uk, 14 items):
Age (40-90)SexWeight + height (computes BMI)Prior fracture (Y/N)Parental hip fracture (Y/N)Current smoking (Y/N)Steroid use (≥ 5 mg/day prednisone ≥ 3 months)Rheumatoid arthritis (Y/N)Secondary osteoporosis (T1DM / hypogonadism / hyperparathyroidism / early menopause, etc., Y/N)Heavy alcohol (≥ 3 units/day, Y/N)Femoral-neck DXA T-score (optional, improves accuracy)
Outputs:
10-year major osteoporotic fracture (MOF) probability, % — includes hip / vertebra / humerus / wrist10-year hip-fracture probability, %
Treatment thresholds (NOF 2014 / AACE 2020):
Absolute indications (treat immediately, no need to compute FRAX):
DXA T ≤ -2.5 (any site: lumbar / total hip / femoral neck)Any fragility fracture (vertebra / hip / wrist / humerus) — even if T is in the osteopenia range
FRAX decision (T between -1.0 and -2.5, osteopenia):
10-year hip fracture ≥ 3% OR10-year major fracture ≥ 20%→ treat pharmacologicallyBelow → lifestyle + nutrition + strength training; no drug needed
Country calibration:
FRAX has 80+ country calibrations (China-male / China-female + separate Hong Kong + Taiwan models)Mainland China calibration is based on a 2003 cohort and may underestimate current risk (population ageing)Some clinicians use the Hong Kong calibration + DXA T < -2.5 dual criteria
FRAX limitations:
Does not include fall frequency + balance + visionDoes not include trabecular bone score (TBS)Does not include vertebral morphology / microfracturesDoes not include some secondary causes (CKD, steroid-dose gradient)Clinical judgment beyond FRAX: repeated falls / very strong family history / abnormal spine imaging → treat even with low FRAX
Practical decision tree:
```
┌─ Any fragility fracture (vertebra/hip/wrist/humerus) → treat immediately (T-score irrelevant)
│
├─ DXA T ≤ -2.5 → treat immediately
│
├─ DXA T between -1.0 and -2.5 (osteopenia) → compute FRAX:
│ ├─ Hip ≥ 3% or MOF ≥ 20% → treat
│ └─ Below → nutrition + exercise, repeat DXA every 2 years
│
└─ DXA T > -1.0 → nutrition + exercise + prevention, repeat every 3-5 years
```
"Should I do DXA?":
Women ≥ 65 + men ≥ 70: routine screeningWomen < 65 / men < 70: only with ≥ 1 major risk factor (early menopause / steroids / family history of fragility fracture / BMI < 18.5 / smoking)Don't do it casually — universal screening of asymptomatic young people is pointless
Chapter 2
Nutrition + exercise
Nutrition + exercise
First-line non-pharmacologic interventions for osteoporosis:
① Calcium:
Women 50+ y/o 1200 mg/day / men 1000-1200 mgFood first: milk / yogurt / cheese / dark leafy greens / calcium-set tofu / small whole fish / fortified foodsNo need to exceed 1200 mg (Bolland 2015 BMJ warned of CV risk, though modern revisions exist)Supplements: with meals + split doses (≤ 500 mg per dose for best absorption)See atlas calcium
② Vitamin D:
50+ y/o 800-1000 IU/day, more if deficient25-hydroxyvitamin D: The storage form of vitamin D in blood — the number measured to check D status. target 30-50 ng/mL (75-125 nmol/L)Combine food + sun + supplementsMultiple L4s on atlas vitamin-d
③ Protein:
1.0-1.2 g/kg/day (healthy elderly) / 1.2-1.5 g/kg/day (fracture recovery / chronic disease)25-40 g per meal + 2.5 g leucine to trigger MPS (atlas protein/muscle L4)"Elderly should eat less protein" is a wrong cultural expectation (atlas sarcopenia)
④ Vitamin K2:
MGP + osteocalcin γ-carboxylation (atlas vitamin-k2/bone L4)Rotterdam cohort: high K2 intake → ↓ CHD 57% + ↓ aortic calcification 52%MK-7 90-180 µg/day + MK-4 45 mg/day (higher dose)Food: natto (the MK-7 king) / certain hard cheeses (MK-4)
⑤ Magnesium + zinc + B12 + folate:
Comprehensive bone-health nutrients; supplement if deficientMg 320-420 mg/day (elemental)See atlas magnesium / zinc / b12 / folate
⑥ Strength training (strongest non-pharmacologic intervention):
Mechanical loading → osteoblast activation → ↑ BMD2-3 sessions/week, focus on hip + spine + wrist (fracture-prone sites)Jumping + high-impact: middle-aged women (under 50) doing 30 jumps/day → ↑ hip BMD (Fuchs 2001)Resistance training: barbell squat / deadlift / dumbbell press / row70+ y/o: modified low-impact strength training (atlas sarcopenia)Important: walking / strolling has limited effect on BMD (insufficient mechanical load)
⑦ Fall prevention:
Balance training (tai chi / yoga / single-leg stance): ↓ falls 30-40% in older adults (Sherrington 2017)Home safety: anti-slip mats + handrails + adequate lightingVision correction + hearing check + foot health + avoid sedativesStrength training + balance training + fall prevention = the elderly bone-health triad
⑧ Quit smoking + limit alcohol:
Smoking → ↓ estrogen + directly suppresses osteoblastsAlcohol > 30 g/day → ↓ bone formation + ↑ fall risk
⑨ Long-term PPI / steroids:
Long-term PPI → ↓ Ca/Mg absorption → ↑ fracture risk (atlas conditions/GERD)Long-term steroids → rapidly accelerated osteoporotic fracturesDiscuss dose / duration with the clinician + intensify calcium + D
① Calcium:
Women 50+ y/o 1200 mg/day / men 1000-1200 mgFood first: milk / yogurt / cheese / dark leafy greens / calcium-set tofu / small whole fish / fortified foodsNo need to exceed 1200 mg (Bolland 2015 BMJ warned of CV risk, though modern revisions exist)Supplements: with meals + split doses (≤ 500 mg per dose for best absorption)See atlas calcium
② Vitamin D:
50+ y/o 800-1000 IU/day, more if deficient25-hydroxyvitamin D: The storage form of vitamin D in blood — the number measured to check D status. target 30-50 ng/mL (75-125 nmol/L)Combine food + sun + supplementsMultiple L4s on atlas vitamin-d
③ Protein:
1.0-1.2 g/kg/day (healthy elderly) / 1.2-1.5 g/kg/day (fracture recovery / chronic disease)25-40 g per meal + 2.5 g leucine to trigger MPS (atlas protein/muscle L4)"Elderly should eat less protein" is a wrong cultural expectation (atlas sarcopenia)
④ Vitamin K2:
MGP + osteocalcin γ-carboxylation (atlas vitamin-k2/bone L4)Rotterdam cohort: high K2 intake → ↓ CHD 57% + ↓ aortic calcification 52%MK-7 90-180 µg/day + MK-4 45 mg/day (higher dose)Food: natto (the MK-7 king) / certain hard cheeses (MK-4)
⑤ Magnesium + zinc + B12 + folate:
Comprehensive bone-health nutrients; supplement if deficientMg 320-420 mg/day (elemental)See atlas magnesium / zinc / b12 / folate
⑥ Strength training (strongest non-pharmacologic intervention):
Mechanical loading → osteoblast activation → ↑ BMD2-3 sessions/week, focus on hip + spine + wrist (fracture-prone sites)Jumping + high-impact: middle-aged women (under 50) doing 30 jumps/day → ↑ hip BMD (Fuchs 2001)Resistance training: barbell squat / deadlift / dumbbell press / row70+ y/o: modified low-impact strength training (atlas sarcopenia)Important: walking / strolling has limited effect on BMD (insufficient mechanical load)
⑦ Fall prevention:
Balance training (tai chi / yoga / single-leg stance): ↓ falls 30-40% in older adults (Sherrington 2017)Home safety: anti-slip mats + handrails + adequate lightingVision correction + hearing check + foot health + avoid sedativesStrength training + balance training + fall prevention = the elderly bone-health triad
⑧ Quit smoking + limit alcohol:
Smoking → ↓ estrogen + directly suppresses osteoblastsAlcohol > 30 g/day → ↓ bone formation + ↑ fall risk
⑨ Long-term PPI / steroids:
Long-term PPI → ↓ Ca/Mg absorption → ↑ fracture risk (atlas conditions/GERD)Long-term steroids → rapidly accelerated osteoporotic fracturesDiscuss dose / duration with the clinician + intensify calcium + D
Chapter 3
Male OP + secondary causes
Male OP + secondary causes
Male osteoporosis + secondary osteoporosis are seriously underestimated. This scene treats them separately because they affect 1/3 of fracture patients and have an even higher rate of clinical neglect.
Male osteoporosis:
Epidemiology:
50+ y/o men have ~ 1/4 lifetime fracture risk (vs ~ 1/2 in women)1-year hip-fracture mortality 30-40% in men, higher than women (more comorbidities + later presentation)DXA screening rate in men < 20% (vs ~ 50% in women) — a huge clinical gap
How male osteoporosis differs:
More secondary causes (~ 60% in men vs ~ 30% in women) — must work upLater symptomatic onset (higher peak BMD + no abrupt menopausal drop)Often dismissed as "men don't get osteoporosis" → missed diagnoses
Male secondary causes — mandatory panel:
Hypogonadism (low T): most common reversible cause. Total T + SHBG + bioavailable T (atlas andropause L4)Hyperthyroidism / hypothyroidismPrimary hyperparathyroidism (HPT): parathyroid hormone: Released when blood calcium dips — it pulls calcium back into the blood from bone, kidney, and gut. + Ca + PCushing's syndrome: 24-h urinary cortisol / dexamethasone suppressionLong-term glucocorticoid use (≥ 5 mg prednisone-equivalent ≥ 3 months): the most common iatrogenic causeExcess alcohol (≥ 3 drinks/day): direct osteoblast suppression + fallsSmokingVitamin D deficiency (25-hydroxyvitamin D: The storage form of vitamin D in blood — the number measured to check D status. < 20 ng/mL)Chronic kidney disease (CKD 3-5): CKD-MBD syndromeMultiple myeloma: 50+ y/o + unexplained bone pain / pathological fracture → SPEP + UPEP + free light chainsCeliac diseaseHIV + antiretroviral therapyAnti-androgen therapy (ADT for prostate cancer): huge risk, requires anti-osteoporotic co-therapyAntiepileptics (phenytoin / carbamazepine): accelerate vitamin D metabolism
Male DXA screening timing (Endocrine Society 2012):
All men 70+50-69 with risk factors: any fragility fracture / steroids / hypogonadism / low body weight / smoking / heavy alcohol / androgen deprivation / long-term PPI / antiepileptics
Secondary osteoporosis lab panel (both sexes):
Baseline: CBC + creatinine + Ca + P + 25(OH)D + PTH + thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. + 24-h urinary calcium + LFTsMen: + total T + SHBGWomen with early menopause: + FSH + E2Suspected specific causes: SPEP / UPEP + free light chains (myeloma) / 24-h urinary cortisol (Cushing's) / anti-tissue transglutaminase IgA (celiac)
Treatment adjustments by specific secondary cause:
Glucocorticoid-induced osteoporosis (GIOP): start bisphosphonates immediately (even with T > -1.5) + Ca + D; do not delayMale low T + osteoporosis: TRT evaluation (atlas andropause/trt L4); do not prescribe TRT for borderline symptomsHyperparathyroidism: surgical adenoma removal; osteoporosis often reversesCKD-MBD: cannot use standard bisphosphonates (contraindicated when eGFR < 30); use denosumab (dose-adjusted) or conservative careCeliac: gluten-free diet + nutritional repletion; BMD reverses over 1-2 years
"Men don't get osteoporosis" must be broken:
Men have worse post-fracture survival (comorbidities)Male socialisation against seeking care → "I can't have osteoporosis" → second-fracture window missedAny fragility fracture in a man = immediate DXA + secondary work-upDon't postpone just because "he can still walk"
Male osteoporosis:
Epidemiology:
50+ y/o men have ~ 1/4 lifetime fracture risk (vs ~ 1/2 in women)1-year hip-fracture mortality 30-40% in men, higher than women (more comorbidities + later presentation)DXA screening rate in men < 20% (vs ~ 50% in women) — a huge clinical gap
How male osteoporosis differs:
More secondary causes (~ 60% in men vs ~ 30% in women) — must work upLater symptomatic onset (higher peak BMD + no abrupt menopausal drop)Often dismissed as "men don't get osteoporosis" → missed diagnoses
Male secondary causes — mandatory panel:
Hypogonadism (low T): most common reversible cause. Total T + SHBG + bioavailable T (atlas andropause L4)Hyperthyroidism / hypothyroidismPrimary hyperparathyroidism (HPT): parathyroid hormone: Released when blood calcium dips — it pulls calcium back into the blood from bone, kidney, and gut. + Ca + PCushing's syndrome: 24-h urinary cortisol / dexamethasone suppressionLong-term glucocorticoid use (≥ 5 mg prednisone-equivalent ≥ 3 months): the most common iatrogenic causeExcess alcohol (≥ 3 drinks/day): direct osteoblast suppression + fallsSmokingVitamin D deficiency (25-hydroxyvitamin D: The storage form of vitamin D in blood — the number measured to check D status. < 20 ng/mL)Chronic kidney disease (CKD 3-5): CKD-MBD syndromeMultiple myeloma: 50+ y/o + unexplained bone pain / pathological fracture → SPEP + UPEP + free light chainsCeliac diseaseHIV + antiretroviral therapyAnti-androgen therapy (ADT for prostate cancer): huge risk, requires anti-osteoporotic co-therapyAntiepileptics (phenytoin / carbamazepine): accelerate vitamin D metabolism
Male DXA screening timing (Endocrine Society 2012):
All men 70+50-69 with risk factors: any fragility fracture / steroids / hypogonadism / low body weight / smoking / heavy alcohol / androgen deprivation / long-term PPI / antiepileptics
Secondary osteoporosis lab panel (both sexes):
Baseline: CBC + creatinine + Ca + P + 25(OH)D + PTH + thyroid-stimulating hormone: A pituitary hormone that prods the thyroid to work — it rises when the thyroid is underactive. + 24-h urinary calcium + LFTsMen: + total T + SHBGWomen with early menopause: + FSH + E2Suspected specific causes: SPEP / UPEP + free light chains (myeloma) / 24-h urinary cortisol (Cushing's) / anti-tissue transglutaminase IgA (celiac)
Treatment adjustments by specific secondary cause:
Glucocorticoid-induced osteoporosis (GIOP): start bisphosphonates immediately (even with T > -1.5) + Ca + D; do not delayMale low T + osteoporosis: TRT evaluation (atlas andropause/trt L4); do not prescribe TRT for borderline symptomsHyperparathyroidism: surgical adenoma removal; osteoporosis often reversesCKD-MBD: cannot use standard bisphosphonates (contraindicated when eGFR < 30); use denosumab (dose-adjusted) or conservative careCeliac: gluten-free diet + nutritional repletion; BMD reverses over 1-2 years
"Men don't get osteoporosis" must be broken:
Men have worse post-fracture survival (comorbidities)Male socialisation against seeking care → "I can't have osteoporosis" → second-fracture window missedAny fragility fracture in a man = immediate DXA + secondary work-upDon't postpone just because "he can still walk"
Chapter 4
Anti-OP drugs
Anti-OP drugs
Pharmacotherapy (high-risk + already-fractured patients):
Indications (ACR / Endocrine Society 2020):
DXA T ≤ -2.5 (any site)Prior fragility fracture + T between -2.5 and -1.0 (osteopenia + fracture)FRAX 10-year hip fracture ≥ 3% or major fracture ≥ 20%
① Bisphosphonates · first-line:
Inhibit osteoclasts → ↓ bone resorption → ↑ BMDAlendronate 70 mg/week: first-line, cheapRisedronate / ibandronateZoledronic acid 5 mg/year IV (Black 2007 NEJM HORIZON): for patients unable to take orally or with poor adherence; vertebral fracture risk ↓ 70%Side effects: esophageal irritation (oral) + rare osteonecrosis of the jaw (ONJ) + atypical femur fracture (AFF) (long-term ≥ 5-year use)Administration: fasting + large glass of water + remain upright 30 minutes (oral)Duration: typically 3-5 years, then a drug holiday of 1-2 years — continue in high-risk patients
Indications (ACR / Endocrine Society 2020):
DXA T ≤ -2.5 (any site)Prior fragility fracture + T between -2.5 and -1.0 (osteopenia + fracture)FRAX 10-year hip fracture ≥ 3% or major fracture ≥ 20%
① Bisphosphonates · first-line:
Inhibit osteoclasts → ↓ bone resorption → ↑ BMDAlendronate 70 mg/week: first-line, cheapRisedronate / ibandronateZoledronic acid 5 mg/year IV (Black 2007 NEJM HORIZON): for patients unable to take orally or with poor adherence; vertebral fracture risk ↓ 70%Side effects: esophageal irritation (oral) + rare osteonecrosis of the jaw (ONJ) + atypical femur fracture (AFF) (long-term ≥ 5-year use)Administration: fasting + large glass of water + remain upright 30 minutes (oral)Duration: typically 3-5 years, then a drug holiday of 1-2 years — continue in high-risk patients
Denosumab + anabolics
② Denosumab · receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone. mAb (Cummings 2009 NEJM FREEDOM):Anti-RANKL mAb → blocks osteoclast differentiation (atlas bone L3 covers RANKL/OPG)60 mg SC every 6 monthsPotent: vertebral fracture ↓ 68%, hip ↓ 40%Critical warning: stopping → rapid BMD loss + rebound multiple vertebral fractures → must bridge with a bisphosphonate, never simply discontinueSuited to patients committed to long-term therapy + unable to take bisphosphonates (CKD etc.)
③ Teriparatide / Abaloparatide (parathyroid hormone: Released when blood calcium dips — it pulls calcium back into the blood from bone, kidney, and gut. analogues):
Stimulate osteoblasts → true bone gain (not just resorption inhibition)SC injection, expensive, for severe osteoporosis + multiple fracturesDuration ≤ 2 years + followed by anti-resorptive (bisphosphonate / denosumab) consolidationContraindicated: prior osteosarcoma / irradiated bone / hypercalcemia
④ Romosozumab (anti-sclerostin mAb):
Dual action: bone formation + resorption inhibition (sclerostin suppresses osteoblasts; blocking it favours formation)Monthly SC × 12 months + follow with a bisphosphonatePotent: greater BMD gain and fracture reduction than bisphosphonates and denosumabCardiovascular warning: ARCH trial showed slightly increased MACE; contraindicated in those with prior CV disease
Hormones / male / long-term
⑤ Estrogen + SERMs:HRT: early perimenopause (initiated at 50-59 + short term), see atlas perimenopause/mht L4Raloxifene (SERM): prevents vertebral fracture, reduces breast cancer, but ↑ VTEBazedoxifene + estrogen
⑥ Male osteoporosis:
Covered in the previous scene. Bisphosphonates + Ca + D + strength training apply equallyIf low T: evaluate TRT (atlas andropause/trt L4, strict indications)
Treatment duration + long-term management:
Re-evaluate at 3-5 yearsDrug holiday + DXA + bone markers (CTX / P1NP)Multidisciplinary: endocrinology / rheumatology / geriatrics / nutrition / physiotherapy
Drug map + self-check + links
Drug-choice summary:| Patient situation | First-line | Alternative |
|---|---|---|
| Postmenopausal OP, no contraindication | Alendronate oral | Risedronate / Zoledronic IV |
| Esophageal issues / poor adherence | Zoledronic annual / Denosumab | — |
| CKD (eGFR < 30) | Denosumab (dose-adjusted) | — |
| Severe OP / multiple vertebral fractures | Teriparatide / Romosozumab → bisphosphonate | Denosumab |
| Cardiovascular disease | Bisphosphonate (avoid Romosozumab) | Denosumab |
| Male osteoporosis | Alendronate / Zoledronic / Denosumab | + TRT if low T |
| Steroid-induced | Risedronate / Zoledronic | + Ca + D fortification |
Self-check:
Height loss > 4 cm (vs young adulthood) = possible vertebral compression fracture, get X-rayKyphosis + chronic back pain: imaging assessmentAny fragility fracture (fracture from minor fall): immediate DXA + work-up
Connections to other atlas islands:
calcium + bone + bone-deposit L4 (mechanism)vitamin-d + vitamin-k2 (D-K-Ca trio)protein + sarcopenia (protein + muscle)exercise + heat-cold-therapy (strength training + hormesis)perimenopause/mht + andropause (hormones)GERD + long-term PPI (absorption impact)
Chapter 5
RANKL/OPG + bisphos
RANKL/OPG + bisphos
Bone is not stone — it is a living tissue continually being torn down and rebuilt.
Two key cell types:
Osteoblasts: secrete osteoid + osteocalcin → mineralisation → build boneOsteoclasts: large multinucleated cells secreting acid + cathepsin K → digest bone matrix → tear bone down
Key insight (Simonet 1997 + Hofbauer 1999 classics): osteoblasts also secrete:
RANKL (Receptor Activator of nuclear factor kappa B: The cell's inflammation master switch (a transcription factor) — when flipped, it turns inflammation on. Ligand) → activates osteoclast precursors → resorptionOPG (Osteoprotegerin) → a "decoy receptor" binding RANKL → prevents it binding RANK → bone preservation
receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone. / OPG ratio → determines net resorption rate:
RANKL ≫ OPG → bone lossOPG ≫ RANKL → preservation / accretion
Regulators:
↑ RANKL (pro-resorption): chronic parathyroid hormone: Released when blood calcium dips — it pulls calcium back into the blood from bone, kidney, and gut. / steroids / TNFα + IL-1 / interleukin-6: A pro-inflammatory signal molecule (cytokine) released by immune cells during inflammation. / postmenopausal estrogen loss → rapid bone loss in the first 5-10 years
↑ OPG (pro-preservation): mechanical loading (strength + high-impact) / estrogen / vitamin D / K2 / adequate protein / anti-inflammatory diet
Chemistry of the postmenopausal window:
In year 1 of menopause, estrogen plummets → RANKL ↑ + OPG ↓ → ratio rises 2-3 ×Fastest bone loss in the first 5-10 years (-2-5%/year)Not "wait until DXA at 65" — but "intervene starting year 1 of menopause"
Osteoclast resorption chemistry (acid pit):
Attaches to bone surface → forms a ruffled-border sealed compartmentV-ATPase + CLC-7 → pump H⁺ → pH 4.5Hydroxyapatite dissolves in acid → Ca²⁺ + PO₄³⁻ releasedCathepsin K + MMP-9 → digest collagen
Bisphosphonate 4-step mechanism:
1. Deposit on bone surface: P-C-P backbone has extreme affinity for hydroxyapatite; half-life of years to over a decade
2. Silent dormancy: no effect when osteoclasts are inactive
3. Osteoclast ingestion: while resorbing the bone surface, the cell "mistakenly ingests" drug-containing HA; the acid pit at pH 4.5 releases it intracellularly
4. Apoptosis at 48-72 h: nitrogen bisphosphonates inhibit FPPS → small GTPases fail to undergo prenylation → cytoskeleton collapse
Clinical results:
Black 2007 NEJM HORIZON (zoledronic acid 5 mg/year IV): vertebral fractures ↓ 70%, hip fractures ↓ 41%Cummings 2009 NEJM FREEDOM (denosumab 60 mg/6 months): vertebral ↓ 68%, hip ↓ 40%
Denosumab rebound warning:
Stopping → 6-12 months later, RANKL signalling returns + risk of multiple vertebral fracturesMust bridge with one IV zoledronate dose — never simply discontinue
Drugs ≠ the final answer:
Build reserve at 35-50: nutrition + strength training + appropriate body weightEarly menopausal intervention: HRT evaluation (atlas perimenopause/mht L4) + strength + Ca + D + K2No drug fully substitutes for the mechanical stimulus of strength training
Atlas connections: osteoporosis + bone/hormones + calcium/blood + calcium/bone-deposit + vitamin-d + vitamin-k2 + protein/muscle + sarcopenia + perimenopause/mht + andropause.
Two key cell types:
Osteoblasts: secrete osteoid + osteocalcin → mineralisation → build boneOsteoclasts: large multinucleated cells secreting acid + cathepsin K → digest bone matrix → tear bone down
Key insight (Simonet 1997 + Hofbauer 1999 classics): osteoblasts also secrete:
RANKL (Receptor Activator of nuclear factor kappa B: The cell's inflammation master switch (a transcription factor) — when flipped, it turns inflammation on. Ligand) → activates osteoclast precursors → resorptionOPG (Osteoprotegerin) → a "decoy receptor" binding RANKL → prevents it binding RANK → bone preservation
receptor activator of NF-κB ligand: A signal molecule that tells osteoclasts to break down bone. / OPG ratio → determines net resorption rate:
RANKL ≫ OPG → bone lossOPG ≫ RANKL → preservation / accretion
Regulators:
↑ RANKL (pro-resorption): chronic parathyroid hormone: Released when blood calcium dips — it pulls calcium back into the blood from bone, kidney, and gut. / steroids / TNFα + IL-1 / interleukin-6: A pro-inflammatory signal molecule (cytokine) released by immune cells during inflammation. / postmenopausal estrogen loss → rapid bone loss in the first 5-10 years
↑ OPG (pro-preservation): mechanical loading (strength + high-impact) / estrogen / vitamin D / K2 / adequate protein / anti-inflammatory diet
Chemistry of the postmenopausal window:
In year 1 of menopause, estrogen plummets → RANKL ↑ + OPG ↓ → ratio rises 2-3 ×Fastest bone loss in the first 5-10 years (-2-5%/year)Not "wait until DXA at 65" — but "intervene starting year 1 of menopause"
Osteoclast resorption chemistry (acid pit):
Attaches to bone surface → forms a ruffled-border sealed compartmentV-ATPase + CLC-7 → pump H⁺ → pH 4.5Hydroxyapatite dissolves in acid → Ca²⁺ + PO₄³⁻ releasedCathepsin K + MMP-9 → digest collagen
Bisphosphonate 4-step mechanism:
1. Deposit on bone surface: P-C-P backbone has extreme affinity for hydroxyapatite; half-life of years to over a decade
2. Silent dormancy: no effect when osteoclasts are inactive
3. Osteoclast ingestion: while resorbing the bone surface, the cell "mistakenly ingests" drug-containing HA; the acid pit at pH 4.5 releases it intracellularly
4. Apoptosis at 48-72 h: nitrogen bisphosphonates inhibit FPPS → small GTPases fail to undergo prenylation → cytoskeleton collapse
Clinical results:
Black 2007 NEJM HORIZON (zoledronic acid 5 mg/year IV): vertebral fractures ↓ 70%, hip fractures ↓ 41%Cummings 2009 NEJM FREEDOM (denosumab 60 mg/6 months): vertebral ↓ 68%, hip ↓ 40%
Denosumab rebound warning:
Stopping → 6-12 months later, RANKL signalling returns + risk of multiple vertebral fracturesMust bridge with one IV zoledronate dose — never simply discontinue
Drugs ≠ the final answer:
Build reserve at 35-50: nutrition + strength training + appropriate body weightEarly menopausal intervention: HRT evaluation (atlas perimenopause/mht L4) + strength + Ca + D + K2No drug fully substitutes for the mechanical stimulus of strength training
Atlas connections: osteoporosis + bone/hormones + calcium/blood + calcium/bone-deposit + vitamin-d + vitamin-k2 + protein/muscle + sarcopenia + perimenopause/mht + andropause.